INTESTINAL Publication-derived

Wnt-Surrogate Molecules Enable Defined Intestinal Organoid

Source Janda et al. · Stanford University School of Medicine, Stanford, USA · 10.1038/nature22306

👤 Janda CY, Dang LT, You C, Chang J, de Lau W, Zhong ZA, Yan KS, Marecber O, Sumer D, Li X, Waber N, Kim Y, Ber R, Ber Y, Garcia KC, Clevers H, Kuo CJ ⏱ 10080 min 🧫 Primary (Mouse and Human Intestinal Crypts)

Abstract

Engineered a water-soluble next-generation surrogate Wnt agonist that bypasses the need for lipid-modified Wnt3A in intestinal organoid culture. NGS-Wnt provides equivalent stem cell support with superior stability and batch-to-batch consistency, enabling defined and GMP-compatible organoid culture conditions.

Cell source

Primary (Mouse and Human Intestinal Crypts)

Application

Defined Organoid Culture

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Janda et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence